Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 18.8% in April

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 67,000 shares, a decline of 18.8% from the March 31st total of 82,500 shares. Based on an average daily volume of 443,600 shares, the days-to-cover ratio is presently 0.2 days.

Shares of NASDAQ:ENLV traded down $0.32 during trading on Tuesday, hitting $11.14. The company’s stock had a trading volume of 141,845 shares, compared to its average volume of 375,608. The business has a 50 day moving average price of $11.47 and a two-hundred day moving average price of $11.99. The company has a market capitalization of $175.57 million, a PE ratio of -15.49 and a beta of 1.14. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.23 and a current ratio of 7.23. Enlivex Therapeutics has a fifty-two week low of $4.49 and a fifty-two week high of $29.40.

A hedge fund recently bought a new stake in Enlivex Therapeutics stock. Compagnie Lombard Odier SCmA purchased a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,000 shares of the company’s stock, valued at approximately $267,000. Compagnie Lombard Odier SCmA owned approximately 0.16% of Enlivex Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 2.39% of the company’s stock.

ENLV has been the topic of a number of research analyst reports. HC Wainwright boosted their target price on Enlivex Therapeutics from $22.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, March 2nd. Zacks Investment Research downgraded shares of Enlivex Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 9th.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. operates as a clinical stage macrophage reprogramming immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions.

Featured Article: Profit margin is different from the revenue

Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.